Drugmaker Johnson & Johnson has joined the chorus of businesses asking U.S. health regulators to develop basic safety rules for cannabinoids in foods and dietary supplements.
Speaking Tuesday to an advisory panel of the U.S. Food and Drug Administration, an executive at the company’s pharmaceutical arm suggested the FDA could “start to chip away” at the unanswered questions about cannabinoids such as CBD.
ADVERTISEMENT
Cynthia Afshari, vice president and global head of preclinical sciences and translational safety at the Janssen Pharmaceutical Cos. of J&J, said the FDA could consider interim steps as it gathers more data about the safety of over-the-counter cannabinoids.
“There are some really high-quality tools that the agency has at their disposal that could start to chip away at least at putting that high quality kind of mechanistic information out there that then could be picked up by others,” Afshari said in comments reported by
Read full article on Marijuana Business Daily
